⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1218493 | 0.92 | — | — | |
| SCHEMBL10763256 | 0.80 | — | — | |
| SCHEMBL14198193 | 0.77 | — | — | |
| SCHEMBL17320217 | 0.77 | — | — | |
| SCHEMBL14085156 | 0.77 | — | — | |
| SCHEMBL6381448 | 0.77 | — | — | |
| SCHEMBL1712830 | 0.77 | — | — | |
| SCHEMBL4523693 | 0.77 | — | — | |
| SCHEMBL68508 | 0.73 | — | — | |
| SCHEMBL8575220 | 0.73 | GAA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426404-B2 | e.g. 3-[1-(6-Amino-pyrimidin-4-yl)-1H-benzoimidazol-2-ylamino]-4-methyl-N-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-phenyl]-benzamide; receptor and non-receptor tyrosine kinases and serine/threonine kinases inhibitor; antiproliferative agent; immune and nervous system disorders | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | claimed |
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | claimed |
| EP-1899329-B1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-05 | — | — | EP | claimed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | claimed |
| JP-4688876-B2 | — | — | 2011-05-25 | — | — | JP | claimed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | claimed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | claimed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | claimed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | claimed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| WO-2001030768-A9 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS INC (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1226129-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| EP-1200111-A1 | COMPOSITIONS FOR THE TREATMENT OF THE CATABOLIC STATE OF PROLONGED CRITICAL ILLNESS | NOVO NORDISK A/S (DK) | 2002-05-02 | — | — | EP | claimed |
| WO-2001098278-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | claimed |
| WO-2000074702-A1 | COMPOSITIONS FOR THE TREATMENT OF THE CATABOLIC STATE OF PROLONGED CRITICAL ILLNESS | NOVO NORDISK A/S (DK) | 2000-12-14 | — | — | WO | claimed |
| EP-0736039-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1996-10-09 | — | — | EP | claimed |
| WO-1995017423-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | claimed |